TRCT
INBX

Tower Research Capital (TRC)’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Tower Research Capital (TRC)’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-398
Closed -$13.9K – 6214
2024
Q1 		$13.9K Sell
398
-5,239
-93% -$191K ﹤0.01% 3354
2023
Q4 		$214K Sell
5,637
-269
-5% -$5.76K ﹤0.01% 2051
2023
Q3 		$108K Buy
5,906
+3,471
+143% +$72.6K ﹤0.01% 1926
2023
Q2 		$63.2K Sell
2,435
-3,913
-62% -$91.4K ﹤0.01% 2390
2023
Q1 		$120K Buy
6,348
+1,412
+29% +$32.8K ﹤0.01% 1699
2022
Q4 		$121K Sell
4,936
-717
-13% -$21.1K 0.01% 1686
2022
Q3 		$101K Buy
5,653
+1,115
+25% +$20.1K ﹤0.01% 2557
2022
Q2 		$52K Buy
4,538
+3,178
+234% +$46.8K ﹤0.01% 2851
2022
Q1 		$30K Sell
1,360
-808
-37% -$20.6K ﹤0.01% 3169
2021
Q4 		$95K Buy
2,168
+1,901
+712% +$76K ﹤0.01% 2264
2021
Q3 		$9K Sell
267
-626
-70% -$19K ﹤0.01% 4511
2021
Q2 		$25K Sell
893
-295
-25% -$6.14K ﹤0.01% 3712
2021
Q1 		$24K Buy
1,188
+414
+53% +$12.1K ﹤0.01% 3761
2020
Q4 		$26K Buy
+774
New +$20.6K ﹤0.01% 3711

Other funds holding INBX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Tower Research Capital (TRC)'s INBX Position: Q2 2024 in Review

Tower Research Capital (TRC) sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 398 shares — an estimated $13.9K sold.

Tower Research Capital (TRC) first reported a position in INBX in Q4 2020 and held it in 14 quarters. The position peaked at $214K in Q4 2023. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

  • Tower Research Capital (TRC) reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 398 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $13.9K.
  • Tower Research Capital (TRC) first reported a position in Inhibrx, Inc. Common Stock in Q4 2020 and held it in 14 quarters.
  • Tower Research Capital (TRC)'s Inhibrx, Inc. Common Stock position peaked at $214K in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2024, filed 13 Aug 2024.